BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen S, Zhaori G. Potential clinical applications of siRNA technique: benefits and limitations: CLINICAL APPLICATION OF SIRNA TECHNIQUE. European Journal of Clinical Investigation 2011;41:221-32. [DOI: 10.1111/j.1365-2362.2010.02400.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Valentic A, Müller J, Hubbuch J. Effects of Different Lengths of a Nucleic Acid Binding Region and Bound Nucleic Acids on the Phase Behavior and Purification Process of HBcAg Virus-Like Particles. Front Bioeng Biotechnol 2022;10:929243. [DOI: 10.3389/fbioe.2022.929243] [Reference Citation Analysis]
2 Yamazaki J, Inoue I, Arakawa A, Karakawa S, Takahashi K, Nakayama A. Simultaneous quantification of oligo-nucleic acids and a ferritin nanocage by size-exclusion chromatography hyphenated to inductively coupled plasma mass spectrometry for developing drug delivery systems. Anal Methods 2022. [PMID: 35616084 DOI: 10.1039/d2ay00068g] [Reference Citation Analysis]
3 Agarwal A, Sarma DK, Chaurasia D, Maan HS. Novel molecular approaches to combat vectors and vector-borne viruses: Special focus on RNA interference (RNAi) mechanisms. Acta Trop 2022;233:106539. [PMID: 35623398 DOI: 10.1016/j.actatropica.2022.106539] [Reference Citation Analysis]
4 Kumar K, Rani V, Mishra M, Chawla R. New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Díez-tercero L, Delgado LM, Perez RA. Modulation of Macrophage Response by Copper and Magnesium Ions in Combination with Low Concentrations of Dexamethasone. Biomedicines 2022;10:764. [DOI: 10.3390/biomedicines10040764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Rosch JC, Hoogenboezem EN, Sorets AG, Duvall CL, Lippmann ES. Albumin-Binding Aptamer Chimeras for Improved siRNA Bioavailability. Cell Mol Bioeng 2022;15:161-73. [PMID: 35401842 DOI: 10.1007/s12195-022-00718-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bownes LV, Williams AP, Marayati R, Quinn CH, Hutchins SC, Stewart JE, Vu T, Easlick JL, Mroczek-Musulman E, Crossman DK, Anderson JC, Willey CD, Datta PK, Beierle EA. Serine-Threonine Kinase Receptor-Associated Protein (STRAP) Knockout Decreases the Malignant Phenotype in Neuroblastoma Cell Lines. Cancers (Basel) 2021;13:3201. [PMID: 34206917 DOI: 10.3390/cancers13133201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Lujan H, Romer E, Salisbury R, Hussain S, Sayes C. Determining the Biological Mechanisms of Action for Environmental Exposures: Applying CRISPR/Cas9 to Toxicological Assessments. Toxicol Sci 2020;175:5-18. [PMID: 32105327 DOI: 10.1093/toxsci/kfaa028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Ren Y, Liu X, Ge H, Guo Y, Zhang Q, Xie M, Wang P, Zhu X, Zhang C. A Combinatorial Approach Based on Nucleic Acid Assembly and Electrostatic Compression for siRNA Delivery. Chem Res Chin Univ 2021;37:906-13. [DOI: 10.1007/s40242-021-1168-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Rosch JC, Hoogenboezem EN, Sorets AG, Duvall CL, Lippmann ES. Albumin-binding Aptamer Chimeras for Improved siRNA Bioavailability.. [DOI: 10.1101/2021.04.15.440012] [Reference Citation Analysis]
11 Khelghati N, Soleimanpour Mokhtarvand J, Mir M, Alemi F, Asemi Z, Sadeghpour A, Maleki M, Samadi Kafil H, Jadidi-Niaragh F, Majidinia M, Yousefi B. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy. Chem Biol Drug Des 2021;97:997-1015. [PMID: 33458952 DOI: 10.1111/cbdd.13824] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Gangopadhyay S, Nikam RR, Gore KR. Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics. Nucleic Acid Ther 2021;31:245-70. [PMID: 33595381 DOI: 10.1089/nat.2020.0882] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
13 Xiao D, Li Y, Tian T, Zhang T, Shi S, Lu B, Gao Y, Qin X, Zhang M, Wei W, Lin Y. Tetrahedral Framework Nucleic Acids Loaded with Aptamer AS1411 for siRNA Delivery and Gene Silencing in Malignant Melanoma. ACS Appl Mater Interfaces 2021;13:6109-18. [PMID: 33497198 DOI: 10.1021/acsami.0c23005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
14 Jain S, Raza K, Agrawal AK, Vaidya A. Therapeutic based on small interfering RNA (siRNA). Nanotechnology Applications for Cancer Chemotherapy 2021. [DOI: 10.1016/b978-0-12-817846-1.00013-8] [Reference Citation Analysis]
15 Fang Y, Zhang K. Cationic vs. non-cationic polymeric vectors for nucleic acid delivery. Reference Module in Materials Science and Materials Engineering 2021. [DOI: 10.1016/b978-0-12-822425-0.00024-5] [Reference Citation Analysis]
16 Taniguchi T, Endo KI, Tanioka H, Sasaoka M, Tashiro K, Kinoshita S, Kageyama M. Novel use of a chemically modified siRNA for robust and sustainable in vivo gene silencing in the retina. Sci Rep 2020;10:22343. [PMID: 33339841 DOI: 10.1038/s41598-020-79242-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
17 Tan HW, Xu YM, Qin SH, Chen GF, Lau ATY. Epigenetic regulation of angiogenesis in lung cancer. J Cell Physiol 2021;236:3194-206. [PMID: 33078404 DOI: 10.1002/jcp.30104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
18 Zhang H, Chen J, Wang H, Lu X, Li K, Yang C, Wu F, Xu Z, Nie H, Ding B, Guo Z, Li Y, Wang J, Li Y, Dai Z. Serum Metabolomics Associating With Circulating MicroRNA Profiles Reveal the Role of miR-383-5p in Rat Hippocampus Under Simulated Microgravity. Front Physiol 2020;11:939. [PMID: 33013433 DOI: 10.3389/fphys.2020.00939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Pang L, Shah H, Wang H, Shu D, Qian SY, Sathish V. EpCAM-Targeted 3WJ RNA Nanoparticle Harboring Delta-5-Desaturase siRNA Inhibited Lung Tumor Formation via DGLA Peroxidation. Mol Ther Nucleic Acids 2020;22:222-35. [PMID: 33230429 DOI: 10.1016/j.omtn.2020.08.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
20 Chen L, Wang S, Liu Q, Zhang Z, Lin S, Zheng Q, Cheng M, Li Y, Cheng C. Reduction sensitive nanocarriers mPEG-g-γ-PGA/SSBPEI@siRNA for effective targeted delivery of survivin siRNA against NSCLC. Colloids Surf B Biointerfaces 2020;193:111105. [PMID: 32417465 DOI: 10.1016/j.colsurfb.2020.111105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
21 Cruz W, Huang H, Barber B, Pasini E, Ding L, Zheng G, Chen J, Bhat M. Lipoprotein-Like Nanoparticle Carrying Small Interfering RNA Against Spalt-Like Transcription Factor 4 Effectively Targets Hepatocellular Carcinoma Cells and Decreases Tumor Burden. Hepatol Commun 2020;4:769-82. [PMID: 32363325 DOI: 10.1002/hep4.1493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Abdeldayem A, Raouf YS, Constantinescu SN, Moriggl R, Gunning PT. Advances in covalent kinase inhibitors. Chem Soc Rev 2020;49:2617-87. [DOI: 10.1039/c9cs00720b] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 28.3] [Reference Citation Analysis]
23 Aghamiri S, Jafarpour A, Gomari MM, Ghorbani J, Rajabibazl M, Payandeh Z. siRNA nanotherapeutics: a promising strategy for anti‐HBV therapy. IET nanobiotechnol 2019;13:457-63. [DOI: 10.1049/iet-nbt.2018.5286] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
24 Xue H, Ding F, Zhang J, Guo Y, Gao X, Feng J, Zhu X, Zhang C. DNA tetrahedron-based nanogels for siRNA delivery and gene silencing. Chem Commun 2019;55:4222-5. [DOI: 10.1039/c9cc00175a] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 14.5] [Reference Citation Analysis]
25 Qureshi A, Tantray VG, Kirmani AR, Ahangar AG. A review on current status of antiviral siRNA. Rev Med Virol 2018;28:e1976. [PMID: 29656441 DOI: 10.1002/rmv.1976] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 12.6] [Reference Citation Analysis]
26 Zhaori G. RNAi technique, how far is it from pediatrics? Pediatr Investig 2017;1:40-6. [PMID: 32851217 DOI: 10.1002/ped4.12004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Yu C, Ding B, Zhang X, Deng X, Deng K, Cheng Z, Xing B, Jin D, Ma P, Lin J. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo. Biomaterials 2018;155:112-23. [PMID: 29175080 DOI: 10.1016/j.biomaterials.2017.11.014] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
28 Yang C, Zhang J, Ding M, Xu K, Li L, Mao L, Zheng J. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol 2018;20:570-5. [DOI: 10.1007/s12094-017-1774-3] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 14.7] [Reference Citation Analysis]
29 Choudhury H, Gorain B, Pandey M, Kumbhar SA, Tekade RK, Iyer AK, Kesharwani P. Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. Int J Pharm 2017;529:506-22. [PMID: 28711640 DOI: 10.1016/j.ijpharm.2017.07.018] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 13.2] [Reference Citation Analysis]
30 Xiu C, Hua Z, Xiao BS, Tang WJ, Zhou HP, Liu XH. Novel benzopyran derivatives and their therapeutic applications: a patent review (2009-2016). Expert Opin Ther Pat 2017;27:1031-45. [PMID: 28627270 DOI: 10.1080/13543776.2017.1338687] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
31 Li M, Ke QF, Tao SC, Guo SC, Rui BY, Guo YP. Fabrication of hydroxyapatite/chitosan composite hydrogels loaded with exosomes derived from miR-126-3p overexpressed synovial mesenchymal stem cells for diabetic chronic wound healing. J Mater Chem B. 2016;4:6830-6841. [PMID: 32263577 DOI: 10.1039/c6tb01560c] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
32 Zhang CG, Yang SD, Zhu WJ, You BG, Liu Y, Yuan ZQ, Chen WL, Li JZ, Zhou XF, Liu C, Zhang XN. Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene-dependent multidrug resistance. J Biomed Mater Res B Appl Biomater 2017;105:2093-106. [PMID: 27405391 DOI: 10.1002/jbm.b.33748] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
33 Zhou Y, Zhou G, Tian C, Jiang W, Jin L, Zhang C, Chen X. Exosome-mediated small RNA delivery for gene therapy: Therapeutic exosomal small RNA. WIREs RNA 2016;7:758-71. [DOI: 10.1002/wrna.1363] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 8.6] [Reference Citation Analysis]
34 Quan S, Kumar P, Narain R. Cationic Galactose-Conjugated Copolymers for Epidermal Growth Factor (EGFR) Knockdown in Cervical Adenocarcinoma. ACS Biomater Sci Eng 2016;2:853-9. [DOI: 10.1021/acsbiomaterials.6b00085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
35 Friberg S, Nyström AM. NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer? J Nanobiotechnology 2016;14:17. [PMID: 26955956 DOI: 10.1186/s12951-016-0172-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
36 Liu K, Jiang X, Hunziker P. Carbohydrate-based amphiphilic nano delivery systems for cancer therapy. Nanoscale 2016;8:16091-156. [DOI: 10.1039/c6nr04489a] [Cited by in Crossref: 117] [Cited by in F6Publishing: 121] [Article Influence: 16.7] [Reference Citation Analysis]
37 Hill AB, Chen M, Chen CK, Pfeifer BA, Jones CH. Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors. Trends Biotechnol 2016;34:91-105. [PMID: 26727153 DOI: 10.1016/j.tibtech.2015.11.004] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 13.9] [Reference Citation Analysis]
38 Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov 2015;14:843-56. [PMID: 26567702 DOI: 10.1038/nrd4685] [Cited by in Crossref: 292] [Cited by in F6Publishing: 307] [Article Influence: 36.5] [Reference Citation Analysis]
39 Young SW, Stenzel M, Yang JL. Nanoparticle-siRNA: A potential cancer therapy? Crit Rev Oncol Hematol 2016;98:159-69. [PMID: 26597018 DOI: 10.1016/j.critrevonc.2015.10.015] [Cited by in Crossref: 103] [Cited by in F6Publishing: 85] [Article Influence: 12.9] [Reference Citation Analysis]
40 Appolinario CM, Allendorf SD, Peres MG, Fonseca CR, Vicente AF, Antunes JM, Pantoja JC, Megid J. Evaluation of short-interfering RNAs treatment in experimental rabies due to wild-type virus. Braz J Infect Dis 2015;19:453-8. [PMID: 26254692 DOI: 10.1016/j.bjid.2015.05.008] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Kokil GR, Veedu RN, Ramm GA, Prins JB, Parekh HS. Type 2 diabetes mellitus: limitations of conventional therapies and intervention with nucleic acid-based therapeutics. Chem Rev 2015;115:4719-43. [PMID: 25918949 DOI: 10.1021/cr5002832] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 6.4] [Reference Citation Analysis]
42 Li S, Yang G. Development of cystathionine gamma-lyase-specific microRNAs. Science Bulletin 2015;60:503-10. [DOI: 10.1007/s11434-015-0741-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Lee YS, Kim SW. Bioreducible polymers for therapeutic gene delivery. J Control Release 2014;190:424-39. [PMID: 24746626 DOI: 10.1016/j.jconrel.2014.04.012] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
44 Hashimoto Y, Uehara Y, Abu Lila AS, Ishida T, Kiwada H. Activation of TLR9 by incorporated pDNA within PEG-coated lipoplex enhances anti-PEG IgM production. Gene Ther 2014;21:593-8. [DOI: 10.1038/gt.2014.32] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
45 Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TKH, Tang T. Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies. Gene 2014;538:217-27. [DOI: 10.1016/j.gene.2013.12.019] [Cited by in Crossref: 197] [Cited by in F6Publishing: 175] [Article Influence: 21.9] [Reference Citation Analysis]
46 Prados J, Melguizo C, Roldan H, Alvarez PJ, Ortiz R, Arias JL, Aranega A. RNA interference in the treatment of colon cancer. BioDrugs. 2013;27:317-327. [PMID: 23553339 DOI: 10.1007/s40259-013-0019-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
47 Abu Lila AS, Uehara Y, Ishida T, Kiwada H. Application of Polyglycerol Coating to Plasmid DNA Lipoplex for the Evasion of the Accelerated Blood Clearance Phenomenon in Nucleic Acid Delivery. Journal of Pharmaceutical Sciences 2014;103:557-66. [DOI: 10.1002/jps.23823] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
48 Kim I, Paek S, Nelson BD, Knight EJ, Marsh MP, Bieber AJ, Bennet KE, Lee KH. Implementation of a chronic unilateral intraparenchymal drug delivery system in a swine model. J Neurosci Methods 2014;227:29-34. [PMID: 24486877 DOI: 10.1016/j.jneumeth.2014.01.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
49 Thakor AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin. 2013;63:395-418. [PMID: 24114523 DOI: 10.3322/caac.21199] [Cited by in Crossref: 377] [Cited by in F6Publishing: 397] [Article Influence: 37.7] [Reference Citation Analysis]
50 Kim JE, Hwang MH, Lee HW, Lee SW, Lee J, Ahn BC. Combined RNA interference of adenine nucleotide translocase-2 and ganciclovir therapy in hepatocellular carcinoma. Nucl Med Biol 2013;40:987-93. [PMID: 24054501 DOI: 10.1016/j.nucmedbio.2013.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Malhotra M, Tomaro-Duchesneau C, Saha S, Prakash S. Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer. Int J Biomater 2013;2013:252531. [PMID: 24159333 DOI: 10.1155/2013/252531] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
52 Eder IE, Egger M, Neuwirt H, Seifarth C, Maddalo D, Desiniotis A, Schäfer G, Puhr M, Bektic J, Cato AC, Klocker H. Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo. Int J Mol Sci 2013;14:11942-62. [PMID: 23736698 DOI: 10.3390/ijms140611942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
53 Liu SV, Fabbri M, Gitlitz BJ, Laird-Offringa IA. Epigenetic therapy in lung cancer. Front Oncol 2013;3:135. [PMID: 23755372 DOI: 10.3389/fonc.2013.00135] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
54 Manfredsson FP. Viral-Mediated Delivery of shRNA and miRNA. Advanced Delivery and Therapeutic Applications of RNAi 2013. [DOI: 10.1002/9781118610749.ch11] [Reference Citation Analysis]
55 Zhao J, Mi Y, Feng S. Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials 2013;34:3411-21. [DOI: 10.1016/j.biomaterials.2013.01.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 7.1] [Reference Citation Analysis]
56 Peng YF, Shi YH, Ding ZB, Zhou J, Qiu SJ, Hui B, Gu CY, Yang H, Liu WR, Fan J. α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy. PLoS One 2013;8:e53072. [PMID: 23468839 DOI: 10.1371/journal.pone.0053072] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
57 Shim G, Choi HW, Lee S, Choi J, Yu YH, Park DE, Choi Y, Kim CW, Oh YK. Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Mol Ther 2013;21:816-24. [PMID: 23380818 DOI: 10.1038/mt.2013.10] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
58 Pileczki V, Braicu C, Gherman CD, Berindan-Neagoe I. TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis. Int J Mol Sci 2012;14:411-20. [PMID: 23263670 DOI: 10.3390/ijms14010411] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
59 Liu C, Zhang N. Emerging biotechnological strategies for non-viral antiangiogenic gene therapy. Angiogenesis 2012;15:521-42. [DOI: 10.1007/s10456-012-9295-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
60 Kanazawa T, Sugawara K, Tanaka K, Horiuchi S, Takashima Y, Okada H. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG–PCL nanomicelles. European Journal of Pharmaceutics and Biopharmaceutics 2012;81:470-7. [DOI: 10.1016/j.ejpb.2012.04.021] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
61 Creixell M, Peppas NA. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 2012;7:367-79. [PMID: 26257819 DOI: 10.1016/j.nantod.2012.06.013] [Cited by in Crossref: 241] [Cited by in F6Publishing: 229] [Article Influence: 21.9] [Reference Citation Analysis]
62 Miele E, Spinelli GP, Miele E, Di Fabrizio E, Ferretti E, Tomao S, Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine 2012;7:3637-57. [PMID: 22915840 DOI: 10.2147/IJN.S23696] [Cited by in Crossref: 33] [Cited by in F6Publishing: 91] [Article Influence: 3.0] [Reference Citation Analysis]
63 Lipskaia L, Hadri L, Le Prince P, Esposito B, Atassi F, Liang L, Glorian M, Limon I, Lompre AM, Lehoux S, Hajjar RJ. SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery. Gene Ther 2013;20:396-406. [PMID: 22763406 DOI: 10.1038/gt.2012.50] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
64 Lara MF, González-González E, Speaker TJ, Hickerson RP, Leake D, Milstone LM, Contag CH, Kaspar RL. Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays. Hum Gene Ther 2012;23:816-23. [PMID: 22480249 DOI: 10.1089/hum.2011.211] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
65 Beloor J, Choi CS, Nam HY, Park M, Kim SH, Jackson A, Lee KY, Kim SW, Kumar P, Lee S. Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. Biomaterials 2012;33:1640-50. [DOI: 10.1016/j.biomaterials.2011.11.008] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
66 Budillon A, Carbone C, Di Gennaro E. Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids 2013;44:63-72. [PMID: 22130737 DOI: 10.1007/s00726-011-1167-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
67 Petrova NS, Chernikov IV, Meschaninova MI, Dovydenko IS, Venyaminova AG, Zenkova MA, Vlassov VV, Chernolovskaya EL. Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res 2012;40:2330-44. [PMID: 22080508 DOI: 10.1093/nar/gkr1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
68 Nakajima H, Kubo T, Semi Y, Itakura M, Kuwamura M, Izawa T, Azuma YT, Takeuchi T. A rapid, targeted, neuron-selective, in vivo knockdown following a single intracerebroventricular injection of a novel chemically modified siRNA in the adult rat brain. J Biotechnol 2012;157:326-33. [PMID: 22079868 DOI: 10.1016/j.jbiotec.2011.10.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
69 Pacheco I, Buzea C, Tron V. Towards new therapeutic approaches for malignant melanoma. Expert Rev Mol Med 2011;13. [DOI: 10.1017/s146239941100202x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
70 Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 2011;19:900-14. [PMID: 21981718 DOI: 10.3109/1061186X.2011.622404] [Cited by in Crossref: 156] [Cited by in F6Publishing: 164] [Article Influence: 13.0] [Reference Citation Analysis]
71 Stein DA, Perry ST, Buck MD, Oehmen CS, Fischer MA, Poore E, Smith JL, Lancaster AM, Hirsch AJ, Slifka MK, Nelson JA, Shresta S, Früh K. Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence. J Virol 2011;85:10154-66. [PMID: 21795337 DOI: 10.1128/JVI.05298-11] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
72 Sanches PG, Grüll H, Steinbach OC. See, reach, treat: ultrasound-triggered image-guided drug delivery. Therapeutic Delivery 2011;2:919-34. [DOI: 10.4155/tde.11.63] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
73 Uchida T, Kanazawa T, Kawai M, Takashima Y, Okada H. Therapeutic Effects on Atopic Dermatitis by Anti-RelA Short Interfering RNA Combined with Functional Peptides Tat and AT1002. J Pharmacol Exp Ther 2011;338:443-50. [DOI: 10.1124/jpet.111.180042] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]